ClinicalTrials.gg
RecruitingNCT04270578PREGUpdated Aug 22, 2022

Gestational Diabetes

An observational study in Gestational Diabetes, sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-22.

Sponsored by University Hospital Tuebingen · Observational

How we know

From the registry’s dates

  • Started May 2012; still recruiting 14 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
800
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Diabetes, Gestational with a site in Germany — 6 open to participants now, 6 under way, none of them phase 3. Diabetes, Gestational · Germany.

Started
2012
the only one that year
Observational
6 of 13
4 open now
Registered
6th of 13
by date
Lead sponsor
2 of 13
University Hospital Tuebingen

Among the 13 studies in Diabetes, Gestational with a site in Germany, this one is the only one that started in 2012, is one of 6 observational ones, and was the 6th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

6 of the 13 studies in Diabetes, Gestational with a site in Germany are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Diabetes, Gestational with a site in Germany, or all of them as a file.
02

Study summary

Due to a changed lifestyle with less physical activity, unfavorable diets rich in fat and calories and obesity, the prevalence of diabetes mellitus is increasing worldwide. The diabetes epidemic is associated with significant personal and socio-economic consequences. Despite attempts to prevent the complications of diabetes, this disease is still the leading cause of blindness, chronic renal insufficiency and non-traumatic amputation. It is important to detect early on an increase in blood sugar and treat it accordingly to reduce costs and to minimize the personal suffering of those affected. As the number of patients with type 2 diabetes mellitus continues to rise, the number of young women with gestational diabetes mellitus (GDM) also increases. This is a disorder og glucose metabolism, which occurs for the first time in pregnancy. The causes for this are manifold. Among other causes, the increasing age of the mothers and weight gain during pregnancy are risk factors for gestational diabetes. Although it has been recommended that women with gestational diabetes should be re-examined after the birth of their child, many women have not. The study is a follow-up study to clarify whether insulin secretion disorder in women with and after GDM is a risk factor for the occurrence of type 2 diabetes mellitus.

03

Conditions studied

  • Gestational Diabetes

Keywords

  • gestational diabetes
  • insulin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Pregnant women in gestational week 24+0 till 31+6 and women postpartum who had a documented occurence of GDM in previous pregnancy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated

Enrollment is possible during AND after gestation:

  • Baseline visit (pregnancy): gestational week 24+0 till 31+6
  • Postpartum visits: documented occurence of GDM in previous pregnancy

Exclusion criteria

Exclusion Criteria:

  • Age \< 18years
  • Diabetes Mellitus Type 1 or Type 2
  • \< 60 ml/min/1,73 m2
  • CRP > 1 mg/dl
  • Increased levels of transaminases 2 fold above
  • Preexisting cardiac conditions
  • Weight loss > 10% within 6 months prior to inclusion
  • Psychiatric disorders
  • Chronic alcohol or substance abuse
  • Blood sugar increasing or decreasing drug therapy, e.g. , antidiabetics, insulin
  • only postpartum visits: pregnancy or lactation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
800 participants (estimated)
Patient registry
No

Groups and cohorts

  • Women with GDM
  • Women without GDM
06

What researchers measure

Primary outcomes

  1. Glucose tolerance during 75 g oral glucose tolerance test

    Glucose tolerance, insulin sensitivity and insulin secretion during oral glucose tolerance test

    Time frame: Glycemia from start of glucose tolerance test (0 minutes) until the end (120 minutes)

Secondary outcomes

  1. Glucose tolerance during 75 g oral glucose tolerance test 1, 2, 5, 10 years postpartum

    Glucose tolerance during oral glucose tolerance test

    Time frame: Glycemia from start of glucose tolerance test (0 minutes) until the end (120 minutes)

  2. Body fat distribution

    Measurement of body fat distribution by MRS

    Time frame: Once during pregnancy and 1, 2, 5, and 10 years postpartum

  3. Spiroergometry to assess physical fitness

    Measurement of VO2max (l/min/kg) as a proxy for physical fitness

    Time frame: 1, 2, 5, and 10 years postpartum

  4. BIA (bioimpedance analysis)

    BIA to estimate body fat (%)

    Time frame: Once during pregnancy and 1, 2, 5, and 10 years postpartum

  5. BMI

    Measurement of weight (kg) and height (m) and given as kg/m\^2

    Time frame: Once during pregnancy and 1, 2, 5, and 10 years postpartum

  6. Assessment of cognitive abilities in offspring

    Cognitive skills represented as an intelligence quotient will be assessed Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V)

    Time frame: 6 and 10 years postpartum

  7. Assessment of cognitive, motoric and language development in offspring

    Cognitive, motoric and language development of children will be assessed with the Bayley Scales of Infant and Toddler Development - Third Edition (Bayley-III)

    Time frame: 2 years postpartum

  8. BIA in offspring

    BIA to estimate body composition in offspring

    Time frame: 2, 6 and 10 years postpartum

  9. Electrocardiogram

    10 minute ECG to assess RR distance for calculation of heart rate variability (R wave distance in ms)

    Time frame: 2, 6 and 10 years postpartum

  10. blood sample

    blood sample to assess HbA1C

    Time frame: 6 and 10 years postpartum

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bauer I, Schleger F, Hartkopf J, Veit R, Breuer M, Schneider N, Pauluschke-Frohlich J, Peter A, Preissl H, Fritsche A, Fritsche L. Pre-pregnancy BMI but not mild stress directly influences Interleukin-6 levels and insulin sensitivity during late pregnancy. Front Biosci (Landmark Ed). 2022 Feb 12;27(2):56. doi: 10.31083/j.fbl2702056. PubMed 35226999 ↗
  • Fritsche L, Heni M, Eckstein SS, Hummel J, Schurmann A, Haring HU, Preissl H, Birkenfeld AL, Peter A, Fritsche A, Wagner R. Incretin Hypersecretion in Gestational Diabetes Mellitus. J Clin Endocrinol Metab. 2022 May 17;107(6):e2425-e2430. doi: 10.1210/clinem/dgac095. PubMed 35180296 ↗
  • Fritsche L, Hummel J, Wagner R, Loffler D, Hartkopf J, Machann J, Hilberath J, Kantartzis K, Jakubowski P, Pauluschke-Frohlich J, Brucker S, Horber S, Haring HU, Roden M, Schurmann A, Solimena M, de Angelis MH, Peter A, Birkenfeld AL, Preissl H, Fritsche A, Heni M. The German Gestational Diabetes Study (PREG), a prospective multicentre cohort study: rationale, methodology and design. BMJ Open. 2022 Feb 15;12(2):e058268. doi: 10.1136/bmjopen-2021-058268. PubMed 35168986 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2012 (actual). Primary completion is estimated for May 2027, 179 months after the start.

Of 142 non-industry observational studies under Diabetes, Gestational, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 179 months is above that.

Counting every sponsor, half of 144 studies reached it within 43 months; a quarter within 19 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2019
First posted
Feb 17, 2020
StartActual
May 23, 2012
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2028
Last update
Aug 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04270578
Collaborators
Deutsches Diabeteszentrum (DDZ), Leibniz-Institut Düsseldorf, Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus, TU Dresden, Klinik für Diabetologie an der Medizinischen Klinik - Innenstadt, LMU München, Universitätsklinik Heidelberg, Abteilung Innere Medizin I, Schwerpunkt Endokrinologie und Stoffwechsel, Universitätsklinikum Leipzig, IFB Adipositas Erkrankungen
Responsible party
Sponsor
First posted
Feb 17, 2020
Start date
May 23, 2012
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Aug 22, 2022

Study contacts

Andreas Fritsche, MD
Contact
andreas.fritsche@med.uni-tuebingen.de
+49 7071 29 ext. 82711
Louise Fritsche, PhD
Contact
louise.fritsche@med.uni-tuebingen.de
+49 7071 29 ext. 82711
Andreas Fritsche, MD
principal investigator · University Hospital Tuebingen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion